UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to your GenPharma first quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to turn the conference over to Vincent Perrone. You may begin. Thank you, operator. Good morning, everyone, and welcome to URGEN Pharma's first quarter 2025 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended March 31st, 2025. The press release can be accessed on the investors portion of our website at investors.eurogen.com. Joining me on the call today are Liz Barrett, President and Chief Executive Officer, Dr. Mark Schoenberg, Chief Medical Officer, David Lin, Chief Commercial Officer, and Chris Degnan, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing pre-commercialization activities related to UGN 102, regulatory meetings and decisions, our commercialization strategy and expectations, as well as potential future commercialization activities for UGN 102, if approved, market and revenue opportunities, commercialization activities related to gel mito, our ongoing and planned clinical trials, commercial and clinical milestones, UGN 102 being the primary growth driver for Eurogen, future R&D efforts, and our goals in 2025 financial guidance, among other things. These forward-lo...